Targeted short-lived drug delivery

• US 20090142413A1
• Filed: 01/23/2009
• Published: 06/04/2009
• Est. Priority Date: 11/19/2007
• Status: Abandoned Application

• Current Assignee: Searete LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: Allen, Paul G., Ishikawa, Muriel Y., Myhrvold, Nathan P., Tegreene, Clarence T., Boyden, Edward S., Wood, Lowell L. JR., Hyde, Roderick A., Malaska, Stephen L.
• Application Number:
  US12/321,664
• Publication Number:
  US 20090142413A1
• Time in Patent Office: Days
• US Class Current: 424/649
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 31/7105 Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 31/727 Heparin; Heparan
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 51/1255 Granulates, agglomerates, microspheres
• CPC Class Codes: A61L 2300/258 Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
• CPC Class Codes: A61L 2300/406 Antibiotics
• CPC Class Codes: A61L 2300/41 Anti-inflammatory agents, e.g. NSAIDs
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/42 Anti-thrombotic agents, anticoagulants, anti-platelet agents
• CPC Class Codes: A61L 2300/602 Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 2300/62 Encapsulated active agents, e.g. emulsified droplets
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

An aspect of the disclosure includes a system for delivering therapeutic agents. In an embodiment, the system includes an implantable medical device comprising at least one reservoir that holds at least one therapeutic agent. Additionally the device includes a delivery mechanism that provides non-systemic in vivo delivery of the at least one therapeutic agent to a local area of an animal in a therapeutically-effective concentration, wherein the therapeutically-effective concentration is in excess of a concentration that would produce a toxic effect when administered systemically to the animal. Furthermore, the at least one therapeutic agent has short half-life. A further aspect of the disclosure includes a method of delivering a therapeutic agent in vivo at non-systemic high doses to a localized area of an animal.

Claims

1-24. -24. (canceled)

25. A method of delivering in vivo at least one therapeutic agent to an animal, comprising:

providing non-systemic delivery of the at least one therapeutic agent to a local area of the animal in a therapeutically-effective concentration, wherein the therapeutically-effective concentration is in excess of a concentration that would produce a toxic effect if administered systemically to the animal, and wherein the at least one therapeutic agent has a half-life of about 5 hours or less.

26. The method of claim 25, wherein the non-systemic delivery of the at least one therapeutic agent to a local area of the animal includes delivery to at least one of a joint, a heart, a kidney, a lung, a brain, a liver, a spleen, a blood vessel, a vein, a capillary, a stomach, an intestine, a duodenum, a fallopian tube, a non-vasculaturized area or a bone.

27. The method of claim 25, wherein the at least one therapeutic agent includes an anti-coagulant of blood.

28. The method of claim 27, wherein the anti-coagulant of blood includes tissue plasminogen activator or heparin.

29. The method of claim 25, wherein the at least one therapeutic agent includes an anti-cancer agent.

30. The method of claim 29, wherein the at least one anti-cancer agent includes podophyllotoxin, etoposide, chlorambucil, cisplatin, oxaliplatin, carboplatin or OGX-011.

31. The method of claim 25, wherein the at least one therapeutic agent includes an anti-inflammatory agent.

32. The method of claim 25, wherein the at least one therapeutic agent has a half-life of about 4 hours or less.

33. The method of claim 25, wherein the at least one therapeutic agent has a half-life of about 3 hours or less.

34. The method of claim 25, wherein the at least one therapeutic agent has a half-life of about 2 hours or less.

35. The method of claim 25, wherein the at least one therapeutic agent has a half-life of about 1 hour or less.

36. The method of claim 25, wherein the at least one therapeutic agent includes at least one agent for gene therapy of disease.

37. The method of claim 36, wherein the at least one agent for gene therapy includes a RNA, siRNA, RNAi, DNA.

38. The method of claim 25, wherein the at least one therapeutic agent includes at least one agent to treat cardiac arrhythmia.

39. The method of claim 25, wherein the at least one agent to treat cardiac arrhythmia includes lidocaine, atropine or adenosine.

40. The method of claim 25, wherein the at least one therapeutic agent includes at least one agent to treat a neurological disorder or behavioral disorder.

41. The method of claim 40, wherein the at least one agent to treat a neurological disorder or behavioral disorder includes venlafaxine.

42. The method of claim 25, wherein the at least one therapeutic agent includes at least one agent to treat human airway passages.

43. The method of claim 42, wherein the at least one agent to treat human airway passages includes albuterol.

44. The method of claim 25, wherein the at least one therapeutic agent includes at least one antibiotic agent.

45. The method of claim 44, wherein the at least one antibiotic agent includes at least one of erythromycin or a derivative thereof.

46. The method of claim 25, wherein the at least one therapeutic agent includes at least one cholesterol-lowering therapeutic agent.

47. The method of claim 46, wherein the at least one cholesterol-lowering therapeutic agent includes atorvastatin.

48-68. -68. (canceled)

69. A method of treating a disease or condition in an animal, comprising:

providing non-systemic delivery of the at least one therapeutic agent to a local area of the animal in a therapeutically-effective concentration, wherein the therapeutically-effective concentration is in excess of a concentration that would produce a toxic effect if administered systemically to the animal, and wherein the at least one therapeutic agent has a half-life of about 5 hours or less.

70. The method of claim 69, wherein the non-systemic delivery of the at least one therapeutic agent to a local area of the animal includes delivery to at least one of a joint, a heart, a kidney, a lung, a brain, a liver, a spleen, a blood vessel, a vein, a capillary, a stomach, an intestine, a duodenum, a fallopian tube, a non-vasculaturized area or a bone.

71. The method of claim 69, wherein the at least one therapeutic agent includes an anti-coagulant of blood.

72. The method of claim 71, wherein the anti-coagulant of blood includes tissue plasminogen activator or heparin.

73. The method of claim 69, wherein the at least one therapeutic agent includes an anti-cancer agent.

74. The method of claim 73, wherein the at least one anti-cancer agent includes podophyllotoxin, etoposide, chlorambucil, cisplatin, oxaliplatin, carboplatin or OGX-011.

75. The method of claim 69, wherein the at least one therapeutic agent includes an anti-inflammatory agent.

76. The method of claim 69, wherein the at least one therapeutic agent has a half-life of about 4 hours or less.

77. The method of claim 69, wherein the at least one therapeutic agent has a half-life of about 3 hours or less.

78. The method of claim 69, wherein the at least one therapeutic agent has a half-life of about 2 hours or less.

79. The method of claim 69, wherein the at least one therapeutic agent has a half-life of about 1 hour or less.

80. The method of claim 69, wherein the at least one therapeutic agent includes at least one agent for gene therapy of disease.

81. The method of claim 80, wherein the at least one agent for gene therapy includes a RNA, siRNA, RNAi, DNA.

82. The method of claim 69, wherein the at least one therapeutic agent includes at least one agent to treat cardiac arrhythmia.

83. The method of claim 82, wherein the at least one agent to treat cardiac arrhythmia includes lidocaine, atropine or adenosine.

84. The method of claim 69, wherein the at least one therapeutic agent includes at least one agent to treat a neurological or behavioral disorder.

85. The method of claim 84, wherein the at least one agent to treat a neurological disorder or behavioral disorder includes venlafaxine.

86. The method of claim 69, wherein the at least one therapeutic agent includes at least one agent to treat human airway passages.

87. The method of claim 86, wherein the at least one agent to treat human airway passages includes albuterol.

88. The method of claim 69, wherein the at least one therapeutic agent includes at least one antibiotic agent.

89. The method of claim 88, wherein the at least one antibiotic agent includes at least one of erythromycin or a derivative thereof.

90. The method of claim 69, wherein the at least one therapeutic agent includes at least one cholesterol-lowering therapeutic agent.

91. The method of claim 90, wherein the at least one cholesterol-lowering therapeutic agent includes atorvastatin.